Skip to main content
    L

    Lineage Cell Therapeutics Inc (LCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.80
    -0.11 (-12.45%)

    Market Cap: $231.35M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Lineage Cell Therapeutics Inc (LCTX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Lineage Cell Therapeutics are Protalix Biotherapeutics (PLX), Fate Therapeutics (FATE) and Century Therapeutics (IPSC). By market cap, Lineage Cell Therapeutics ranks 10th of the 13 companies on this page; Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is the largest at $387.16M.

    Peer Comparison

    LCTX's ROIC of -6.7% is above the peer median of -38.3%, and its revenue growth of -61.0% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Lineage Cell Therapeutics (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Fate Therapeutics Inc (FATE)$155.74MN/A29.7x0.0%-51.3%9.2%0.00%
    Century Therapeutics Inc (IPSC)$299.63MN/AN/A0.0%N/A-100.0%0.00%
    Greenwich Lifesciences Inc (GLSI)$219.29MN/AN/A0.0%N/A0.0%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Larimar Therapeutics Inc (LRMR)$313.73MN/AN/A0.0%N/A0.0%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Galectin Therapeutics Inc (GALT)$307.59MN/AN/A0.0%671.1%0.0%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Palisade Bio Inc (PALI)$201.01MN/A436.8x0.0%N/A0.0%0.00%
    Peer median$281.64M12.1x10.4x0.0%-38.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Lineage Cell Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Fate Therapeutics Inc (FATE)
    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally.
    FATE competitors
    Century Therapeutics Inc (IPSC)
    Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy...
    IPSC competitors
    Greenwich Lifesciences Inc (GLSI)
    Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /...
    GLSI competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Larimar Therapeutics Inc (LRMR)
    Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases.
    LRMR competitors
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Galectin Therapeutics Inc (GALT)
    Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic...
    GALT competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Palisade Bio Inc (PALI)
    Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
    PALI competitors

    Frequently Asked Questions About LCTX

    Who are Lineage Cell Therapeutics' main competitors?

    The companies most similar to Lineage Cell Therapeutics include Protalix Biotherapeutics (PLX), Fate Therapeutics (FATE), Century Therapeutics (IPSC), Greenwich Lifesciences (GLSI) and Bicycle Therapeutics (BCYC), listed from the closest match.

    Who is Lineage Cell Therapeutics' biggest competitor?

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is the largest of the similar companies at $387.16M; Protalix Biotherapeutics (PLX) is the closest match by business profile, size, sector and industry.

    How does LCTX stock compare with its competitors?

    LCTX's P/S is 18.7x against a peer median of 10.4x; its net margin is 16.2% against a peer median of 0.0%.

    Which of Lineage Cell Therapeutics' competitors pays a higher dividend?

    Lineage Cell Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Lineage Cell Therapeutics bigger than its competitors?

    No. Lineage Cell Therapeutics is 10th by market cap among the 13 companies on this page; the largest is Contineum Therapeutics, Inc. Class A Common Stock (CTNM) at $387.16M.